Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses (2023 - 2025)

CG Oncology's Accumulated Expenses history spans 3 years, with the latest figure at $24.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 65.07% year-over-year to $24.2 million; the TTM value through Dec 2025 reached $24.2 million, up 65.07%, while the annual FY2025 figure was $24.2 million, 65.07% up from the prior year.
  • Accumulated Expenses reached $24.2 million in Q4 2025 per CGON's latest filing, up from $20.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $24.2 million in Q4 2025 to a low of $5.1 million in Q1 2024.
  • Average Accumulated Expenses over 3 years is $14.7 million, with a median of $14.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 40.43% in 2024, then surged 222.36% in 2025.
  • A 3-year view of Accumulated Expenses shows it stood at $10.4 million in 2023, then skyrocketed by 40.43% to $14.7 million in 2024, then soared by 65.07% to $24.2 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Accumulated Expenses are $24.2 million (Q4 2025), $20.4 million (Q3 2025), and $23.0 million (Q2 2025).